Peptide research profile
Ipamorelin
Also known as NNC 26-0161 · ipamorelin acetate
A randomized phase 2 postoperative-ileus study found no statistically significant improvement in its key or secondary efficacy endpoints. Early volunteer studies establish pharmacology, not wellness benefit.
Low evidenceNot FDA approved
- Evidence maturity
- Early signal
- Regulatory status
- Not FDA approved
- Recorded outcomes
- 3
- Indexed sources
- 3
Educational. Not medical advice.
Summary
An unapproved ghrelin-receptor agonist and growth-hormone secretagogue with limited clinical development.
What is Ipamorelin being studied for?
Growth hormone and gastrointestinal motility
How is it thought to work?
Activates the ghrelin or growth-hormone-secretagogue receptor, stimulating GH release and gastrointestinal motility pathways.
Recorded outcomes
Free account
3 graded outcomes and 3 sources for Ipamorelin.
Outcome table and every source open with a free account. No card.
Update history
Updated
- Editorial review of the profile and its sources.
- Record last updated in the Senzu database.
- Profile first published.